Clinical Factors Associated With Response and Outcomes in Intravenous Ketamine Treatment for Depression: Insights From a Real-World Retrospective Study

PURPOSE: This study aimed to explore the clinical factors associated with response in patients receiving ketamine, evaluating changes in suicidality in each treatment session and the side effects of ketamine infusion therapy for depression. METHODS: A retrospective descriptive study was conducted using electronic medical records from 90 patients treated with subanesthetic ketamine infusions between 2019 and 2023. Depression and suicidality scores were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Clinical response was defined as a 50% or greater reduction in MADRS score at the final treatment session. The primary outcome was clinical factors associated with response in patients treated with ketamine. RESULTS: Of the 90 patients, 35 were classified as responders. Logistic regression analysis identified baseline suicidality scores on MADRS (adjusted OR: 1.46, P=0.019) and comorbid anxiety disorder (adjusted OR: 4.39, P=0.048) as significantly associated with treatment response. Generalized estimating equation analysis revealed that each additional ketamine session was associated with a significant reduction in MADRS (coefficient =-1.11, P<0.001) and suicidality scores (coefficient =-0.14, P<0.001). Side effects occurred more frequently in nonresponders. CONCLUSIONS: These findings suggest that baseline suicidality and comorbid anxiety disorders are important factors to consider when selecting candidates for ketamine therapy. Future research should aim to further elucidate the factors contributing to the efficacy and safety of ketamine as a treatment for depression.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Psychopharmacology
Published
2026-11-19
DOI
https://doi.org/10.1097/jcp.0000000000002302
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Factors Associated With Response and Outcomes in Intravenous Ketamine Treatment for Depression: Insights From a Real-World Retrospective Study

Mayteewat Chiddaycha, Chavit Tunvirachaisakul, Teerayuth Rungnirundorn, Yanin Kiatpanabhikul et al.
2 links
Journal of Clinical Psychopharmacology
Treatment of Major Depression
article

Clinical Factors Associated With Response and Outcomes in Intravenous Ketamine Treatment for Depression: Insights From a Real-World Retrospective Study

Mayteewat Chiddaycha, Chavit Tunvirachaisakul, Teerayuth Rungnirundorn, Yanin Kiatpanabhikul, Thornthep Vichitkunakorn
article en

Abstract

PURPOSE: This study aimed to explore the clinical factors associated with response in patients receiving ketamine, evaluating changes in suicidality in each treatment session and the side effects of ketamine infusion therapy for depression. METHODS: A retrospective descriptive study was conducted using electronic medical records from 90 patients treated with subanesthetic ketamine infusions between 2019 and 2023. Depression and suicidality scores were measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Clinical response was defined as a 50% or greater reduction in MADRS score at the final treatment session. The primary outcome was clinical factors associated with response in patients treated with ketamine. RESULTS: Of the 90 patients, 35 were classified as responders. Logistic regression analysis identified baseline suicidality scores on MADRS (adjusted OR: 1.46, P=0.019) and comorbid anxiety disorder (adjusted OR: 4.39, P=0.048) as significantly associated with treatment response. Generalized estimating equation analysis revealed that each additional ketamine session was associated with a significant reduction in MADRS (coefficient =-1.11, P<0.001) and suicidality scores (coefficient =-0.14, P<0.001). Side effects occurred more frequently in nonresponders. CONCLUSIONS: These findings suggest that baseline suicidality and comorbid anxiety disorders are important factors to consider when selecting candidates for ketamine therapy. Future research should aim to further elucidate the factors contributing to the efficacy and safety of ketamine as a treatment for depression.

Journal of Clinical Psychopharmacology
Chulalongkorn University (TH)
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon